

IPG PHOTONICS CORP
Form 10-Q
August 10, 2009

Table of Contents

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

FORM 10-Q

**QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934**

For the quarterly period ended June 30, 2009

OR

**TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934**

Commission File Number 001-33155

IPG PHOTONICS CORPORATION

(Exact name of registrant as specified in its charter)

**Delaware
(State or other jurisdiction of
incorporation or organization)**

**04-3444218
(I.R.S. Employer
Identification Number)**

**50 Old Webster Road, Oxford, Massachusetts
(Address of principal executive offices)**

**01540
(Zip code)**

(508) 373-1100

(Registrant's telephone number, including area code)

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. YES NO

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data file required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). YES NO

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of large accelerated filer, accelerated filer and smaller reporting company in Rule 12b-2 of the Exchange Act.

Large Accelerated Filer <input type="checkbox"/>	Accelerated Filer <input type="checkbox"/>	Non-Accelerated Filer <input type="checkbox"/> (Do not check if a smaller reporting company)	Smaller Reporting Company <input type="checkbox"/>
---	---	--	---

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). YES NO

As of August 5, 2009, there were 45,523,701 shares of the registrant's common stock issued and outstanding.

TABLE OF CONTENTS

	Page
<u>Part I. Financial Information</u>	3
<u>Item 1. Unaudited Interim Financial Statements</u>	3
<u>Consolidated Balance Sheets: June 30, 2009 and December 31, 2008</u>	3
<u>Consolidated Statements of Operations: Three and Six Months Ended June 30, 2009 and 2008</u>	4
<u>Consolidated Statements of Cash Flows: Six Months Ended June 30, 2009 and 2008</u>	5
<u>Consolidated Statements of Equity: Six Months Ended June 30, 2009 and 2008</u>	6
<u>Notes to Consolidated Financial Statements</u>	7
<u>Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations</u>	12
<u>Item 3. Quantitative and Qualitative Disclosures About Market Risk</u>	17
<u>Item 4. Controls and Procedures</u>	18
<u>Part II. Other Information</u>	18
<u>Item 1. Legal Proceedings</u>	18
<u>Item 1A. Risk Factors</u>	18
<u>Item 2. Unregistered Sales of Equity Securities and Use of Proceeds</u>	20
<u>Item 3. Defaults Upon Senior Securities</u>	20
<u>Item 4. Submission of Matters to a Vote of Security Holders</u>	20
<u>Item 5. Other Information</u>	21
<u>Item 6. Exhibits</u>	21
<u>Signatures</u>	22
<u>EX-31.1 Certification of Chief Executive Officer pursuant to Rule 13a-14(a)</u>	
<u>EX-31.2 Certification of Chief Financial Officer pursuant to Rule 13a-14(a)</u>	
<u>EX-32 Certification of Chief Executive Officer and Chief Financial Officer pursuant to Section 1350</u>	

Table of Contents

PART I FINANCIAL INFORMATION
ITEM 1. UNAUDITED INTERIM FINANCIAL STATEMENTS
IPG PHOTONICS CORPORATION
CONSOLIDATED BALANCE SHEETS

	June 30, 2009	December 31, 2008
	(In thousands, except share and per share date)	
ASSETS		
CURRENT ASSETS:		
Cash and cash equivalents	\$ 78,068	\$ 51,283
Accounts receivable, net	32,006	41,842
Inventories, net	62,085	72,555
Income taxes receivable	1,995	1,968
Prepaid expenses and other current assets	6,138	7,200
Deferred income taxes	9,539	6,175
Total current assets	189,831	181,023
DEFERRED INCOME TAXES	3,008	2,400
PROPERTY, PLANT AND EQUIPMENT, Net	115,258	114,492
OTHER ASSETS	15,004	15,303
TOTAL	\$ 323,101	\$ 313,218
LIABILITIES AND STOCKHOLDERS EQUITY		
CURRENT LIABILITIES:		
Revolving line-of-credit facilities	\$ 31,401	\$ 19,769
Current portion of long-term debt	1,333	1,333
Accounts payable	6,065	7,739
Accrued expenses and other liabilities	18,929	17,988
Deferred income taxes	343	1,690
Income taxes payable	1,653	507
Total current liabilities	59,724	49,026
DEFERRED INCOME TAXES AND OTHER LONG-TERM LIABILITIES	1,819	2,896
LONG-TERM DEBT	17,334	17,997
COMMITMENTS AND CONTINGENCIES IPG PHOTONICS CORPORATION STOCKHOLDERS EQUITY:		
Common stock, \$0.0001 par value, 175,000,000 shares authorized; 45,516,231 shares issued and outstanding at June 30, 2009; 44,965,960 shares issued and outstanding at December 31, 2008	5	4
Additional paid-in capital	289,242	283,217

Edgar Filing: IPG PHOTONICS CORP - Form 10-Q

Accumulated deficit	(53,801)	(53,843)
Accumulated other comprehensive income	8,683	8,794
Total IPG Photonics Corporation stockholders' equity	244,129	238,172
NONCONTROLLING INTERESTS	95	5,127
Total equity	244,224	243,299
TOTAL	\$ 323,101	\$ 313,218

See notes to consolidated financial statements.

Table of Contents

IPG PHOTONICS CORPORATION
CONSOLIDATED STATEMENTS OF OPERATIONS

	Three Months Ended		Six Months Ended	
	June 30,		June 30,	
	2009	2008	2009	2008
	(In thousands, except per share data)			
NET SALES	\$ 40,385	\$ 55,994	\$ 85,793	\$ 108,870
COST OF SALES	28,613	29,047	58,160	57,523
GROSS PROFIT	11,772	26,947	27,633	51,347
OPERATING EXPENSES:				
Sales and marketing	3,880	3,703	7,069	6,850
Research and development	4,734	4,447	8,876	7,321
General and administrative	4,944	5,765	9,934	12,177
(Gain) loss on foreign exchange	(500)	259	1,015	(314)
Total operating expenses	13,058	14,174	26,894	26,034
OPERATING (LOSS) INCOME	(1,286)	12,773	739	25,313
OTHER (EXPENSE) INCOME, NET:				
Interest expense	(367)	(183)	(757)	(278)
Other (expense) income, net	(36)	489	(184)	536
Total other (expense) income	(403)	306	(941)	258
(LOSS) INCOME BEFORE BENEFIT FROM (PROVISION FOR) INCOME TAXES	(1,689)	13,079	(202)	25,571
BENEFIT FROM (PROVISION FOR) INCOME TAXES	524	(4,058)	63	(8,055)
NET (LOSS) INCOME	(1,165)	9,021	(139)	17,516
LESS: NET INCOME (LOSS) ATTRIBUTABLE TO NONCONTROLLING INTERESTS	64	469	(181)	815
NET (LOSS) INCOME ATTRIBUTABLE TO IPG PHOTONICS CORPORATION	\$ (1,229)	\$ 8,552	\$ 42	\$ 16,701
NET (LOSS) INCOME ATTRIBUTABLE TO IPG PHOTONICS CORPORATION PER SHARE:				
Basic	\$ (0.03)	\$ 0.19	\$ 0.00	\$ 0.38
Diluted	\$ (0.03)	\$ 0.19	\$ 0.00	\$ 0.36
WEIGHTED-AVERAGE SHARES OUTSTANDING:				
Basic	45,431	44,355	45,263	44,225

Diluted	45,431	46,132	46,336	46,087
	See notes to consolidated financial statements.			

Table of Contents

IPG PHOTONICS CORPORATION
CONSOLIDATED STATEMENTS OF CASH FLOWS

	Six Months Ended	
	June 30,	
	2009	2008
	(In thousands)	
CASH FLOWS FROM OPERATING ACTIVITIES:		
Net (loss) income	\$ (139)	\$ 17,516
Adjustments to reconcile net (loss) income to net cash provided by operating activities:		
Depreciation and amortization	9,043	7,525
Deferred income taxes	(5,699)	(2,934)
Stock-based compensation	1,205	1,004
Loss (gain) on foreign currency transactions	1,015	(314)
Other	(20)	(204)
Provisions for inventory, warranty and bad debt	6,152	3,489
Changes in assets and liabilities that provided (used) cash:		
Accounts receivable	8,197	(2,846)
Inventories	1,686	(15,751)
Prepaid expenses and other current assets	398	1,032
Accounts payable	(335)	(469)
Accrued expenses and other liabilities	(406)	(330)
Income and other taxes payable	2,703	3,930
Net cash provided by operating activities	23,800	11,648
CASH FLOWS FROM INVESTING ACTIVITIES:		
Purchases of property, plant, equipment and intangible assets	(7,726)	(20,325)
Proceeds from sale of marketable securities		5,450
Other	(54)	136
Net cash used in investing activities	(7,780)	(14,739)
CASH FLOWS FROM FINANCING ACTIVITIES:		
Proceeds from line-of-credit facilities	16,502	14,127
Payments on line-of-credit facilities	(4,716)	(6,041)
Purchases of noncontrolling interests	(508)	
Proceeds from long-term borrowings		20,043
Principal payments on long-term borrowings	(677)	(19,499)
Exercise of employee stock options and related tax benefit from exercise	477	1,365
Net cash provided by financing activities	11,078	9,995
EFFECT OF CHANGES IN EXCHANGE RATES ON CASH AND CASH EQUIVALENTS		
	(313)	50
NET INCREASE IN CASH AND CASH EQUIVALENTS	26,785	6,954
CASH AND CASH EQUIVALENTS Beginning of period	51,283	37,972

CASH AND CASH EQUIVALENTS	End of period	\$ 78,068	\$ 44,926
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:			
Cash paid for interest		\$ 794	\$ 849
Income taxes paid		\$ 5,059	\$ 5,026
Non-cash transactions:			
Additions to property, plant and equipment included in accounts payable		\$ 360	\$ 1,243
Inventory contributed to unconsolidated affiliate		\$ 237	\$
Purchases of noncontrolling interests in exchange for Common Stock		\$ 3,027	\$
See notes to consolidated financial statements.			

Table of Contents

IPG PHOTONICS CORPORATION
CONSOLIDATED STATEMENTS OF EQUITY

	Six Months Ended June 30,			
	2009		2008	
	(In thousands, except share and per share data)			
	Shares	Amount	Shares	Amount
COMMON STOCK				
Balance, beginning of year	44,965,960	\$ 4	44,012,341	\$ 4
Common stock issued in purchase of noncontrolling interests	368,146	1		
Common stock issued under employee stock purchase plan	24,076			
Exercise of stock options	158,049		508,491	
Balance, end of period	45,516,231	5	44,520,832	4
ADDITIONAL PAID-IN CAPITAL				
Balance, beginning of year		283,217		275,506
Common stock issued in purchase of noncontrolling interests		3,027		
Premium on purchase of noncontrolling interests		(712)		
Discount on purchase of noncontrolling interests		2,028		
Common stock issued under employee stock purchase plan		224		
Exercise of stock options and related tax benefit from exercise		253		1,365
Stock-based compensation		1,205		1,004
Balance, end of period		289,242		277,875
ACCUMULATED DEFICIT				
Balance, beginning of year		(53,843)		(90,497)
Net income attributable to IPG Photonics Corporation		42		16,701
Balance, end of period		(53,801)		(73,796)
ACCUMULATED OTHER COMPREHENSIVE INCOME				
Balance, beginning of year		8,794		15,167
Translation adjustments		(446)		6,374
Unrealized loss on marketable securities				(75)
Unrealized gain (loss) on derivatives, net of tax		335		(67)
Balance, end of period		8,683		21,399

TOTAL IPG PHONTONICS CORPORATION STOCKHOLDERS EQUITY	244,129	225,482
NONCONTROLLING INTERESTS		
Balance, beginning of year	5,127	4,455
Net (loss) income attributable to noncontrolling interests	(181)	815
Purchase of noncontrolling interests	(3,535)	
Premium on purchase of noncontrolling interests	712	
Discount on purchase of noncontrolling interests	(2,028)	
Balance, end of period	95	5,270
TOTAL EQUITY	\$ 244,224	\$ 230,752

See notes to consolidated financial statements.

Table of Contents

**IPG PHOTONICS CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**

1. BASIS OF PRESENTATION

The accompanying unaudited interim consolidated financial statements have been prepared by IPG Photonics Corporation, or IPG, we, our, or the Company. Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States of America have been condensed or omitted pursuant to the rules and regulations of the Securities and Exchange Commission. The consolidated financial statements include our accounts and those of our subsidiaries. All intercompany balances have been eliminated in consolidation. These consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto in our annual report on Form 10-K for the year ended December 31, 2008.

Effective January 1, 2009, we adopted Statement of Financial Accounting Standards (SFAS) No. 160, *Noncontrolling Interests in Consolidated Financial Statements – an amendment of ARB No. 51* (SFAS No. 160). SFAS No. 160 was retrospectively applied, and

clarifies that a noncontrolling interest in a subsidiary is an ownership interest in the consolidated entity that should be reported as equity in the consolidated financial statements,

requires consolidated net income to be reported at amounts that include the amounts attributable to both the parent and the noncontrolling interest,

establishes standards for accounting for changes in a parent's ownership interest in a subsidiary, and

requires expanded disclosures that clearly identify and distinguish between interests of the parent's owners and the interests of the noncontrolling owners of a subsidiary.

The calculation of earnings per share continues to be based on income amounts attributable to the parent. SFAS No. 160 was effective for the Company beginning January 1, 2009. The changes in presentation prescribed by SFAS No. 160 are incorporated in the accompanying Consolidated Balance Sheets, Consolidated Statements of Operations, Consolidated Statements of Cash Flows and Consolidated Statements of Equity.

In the opinion of our management, the unaudited financial information for the interim periods presented reflects all adjustments necessary for a fair presentation of our financial position, results of operations and cash flows. The results reported in these consolidated financial statements are not necessarily indicative of results that may be expected for the entire year.

2. RECENT ACCOUNTING PRONOUNCEMENTS

In December 2007, the Financial Accounting Standards Board (FASB) issued SFAS No. 141 (revised 2007), *Business Combinations* (SFAS No. 141 (revised 2007)). SFAS No. 141 (revised 2007) requires an acquirer to measure the identifiable assets acquired, the liabilities assumed and any noncontrolling interest in the acquiree at their fair values on the acquisition date, with goodwill being the excess value over the net identifiable assets acquired. This standard also requires the fair value measurement of certain other assets and liabilities related to the acquisition such as contingencies and research and development. SFAS No. 141 (revised 2007) was required to be applied prospectively beginning January 1, 2009 and did not have a material effect on our financial statements.

In March 2008, the FASB issued SFAS 161, *Disclosures about Derivative Instruments and Hedging Activities* (SFAS 161). SFAS 161 applies to all derivative instruments and non-derivative instruments that are designated and qualify as hedging instruments pursuant to paragraphs 37 and 42 of SFAS 133, *Accounting for Derivative Instruments and Hedging Activities*, (SFAS 133), and related hedged items accounted for under SFAS 133. SFAS 161 requires additional disclosures about (a) how and why an entity uses derivative instruments, (b) how derivative instruments and related hedged items are accounted for under SFAS 133 and its related interpretations, and (c) how derivative instruments and related hedged items affect an entity's financial position, results of operations, and cash flows. SFAS 161 was effective for the Company beginning January 1, 2009. The disclosures prescribed by SFAS 161 are included in Note 7 of these Notes to Consolidated Financial Statements.

Effective June 30, 2009, we adopted Statement of Financial Accounting Standards No. 165 (SFAS No. 165), *Subsequent Events*. SFAS No. 165 defines the subsequent events or transactions period, circumstances under which such events or transactions should be recognized, and disclosures regarding subsequent events or transactions. The adoption of SFAS No. 165 required the Company to provide additional disclosures stating that we consider events or transactions that occur after the balance sheet date but before the financial statements are issued to provide additional evidence relative to certain estimates or to identify matters that require additional disclosure. Subsequent events have been evaluated through August 10, 2009, the date of issuance of these financial statements.

Effective June 30, 2009, we adopted FASB Staff Position (FSP) No. FAS 107-1 and APB 28-1, *Interim Disclosures about Fair Value of Financial Instruments*, which requires disclosures about fair value of financial instruments in interim

Table of Contents

reporting periods as well as in annual financial statements. The adoption of FSP FAS 107-1 and APB 28-1 required the Company to provide additional disclosures, which are included in Note 8.

3. INVENTORIES

Inventories consist of the following (in thousands):

	June 30, 2009	December 31, 2008
Components and raw materials	\$ 22,447	\$ 27,482
Work-in-process	23,704	28,653
Finished goods	15,934	16,420
Total	\$ 62,085	\$ 72,555

The Company recorded inventory provisions totaling \$4.2 million and \$1.6 million for the six months ended June 30, 2009 and 2008, respectively. These provisions were recorded as a result of changes in market prices of certain components, the realizable value of those inventories through finished product sales and uncertainties related to the recoverability of the value of inventories due to technological changes and excess quantities. These provisions are reported as a reduction to components and raw materials and finished goods.

4. FINANCING ARRANGEMENTS

The Company's borrowings under existing financing arrangements consist of the following (in thousands):

	June 30, 2009	December 31, 2008
Revolving Line-of-Credit Facilities:		
Euro Credit and Overdraft Facilities	\$ 1,436	\$ 670
U.S. Line of Credit	29,965	19,099
Total	\$ 31,401	\$ 19,769
Term Debt:		
U.S. Long-Term Note	18,667	19,330
Less current portion	(1,333)	(1,333)
Total long-term debt	\$ 17,334	\$ 17,997

5. NET INCOME ATTRIBUTABLE TO IPG PHOTONICS CORPORATION PER SHARE

The following table sets forth the computation of diluted net income attributable to IPG Photonics Corporation per share (in thousands, except per share data):

Table of Contents

	Three Months Ended June 30,		Six Months Ended June 30,	
	2009	2008	2009	2008
Net income attributable to IPG Photonics Corporation	\$ (1,229)	\$ 8,552	\$ 42	\$ 16,701
Weighted average shares	45,431	44,355	45,263	44,225
Dilutive effect of common stock equivalents		1,778	1,073	1,862
Diluted weighted average common shares	45,431	46,132	46,336	46,087
Basic net income attributable to IPG Photonics	\$ (0.03)	\$ 0.19	\$ 0.00	\$ 0.38
Diluted net income attributable to IPG Photonics Corporation per share	\$ (0.03)	\$ 0.19	\$ 0.00	\$ 0.36

The computation of diluted weighted average common shares excludes options to purchase 2,240,000 shares for the three months ended June 30, 2009, because the effect on net income attributable to IPG Photonics Corporation per share would have been anti-dilutive as a result of the Company's net loss during the period. The computation of diluted weighted average common shares excludes options to purchase 1,153,000 shares for the six months ended June 30, 2009 and 233,000 shares for the three months and six months ended June 30, 2008, because these options were out-of-the-money.

6. COMPREHENSIVE INCOME

Total comprehensive income and its components were as follows (in thousands):

	Three Months Ended June 30,		Six Months Ended June 30,	
	2009	2008	2009	2008
Net (loss) income	\$ (1,229)	\$ 8,552	\$ 42	\$ 16,701
Other comprehensive income (loss):				
Unrealized gain (loss) on secured note interest rate swap	304	(67)	335	(67)
Unrealized loss on marketable securities		(75)		(75)
Foreign currency translation adjustment	6,493	(1)	(446)	6,374
Comprehensive income (loss)	\$ 5,568	\$ 8,409	\$ (69)	\$ 22,933

7. DERIVATIVE FINANCIAL INSTRUMENTS

On January 1, 2009, we adopted SFAS No. 161, which requires enhanced disclosures regarding an entity's derivative and hedging activities as provided below.

Our primary market exposures are to interest rates and foreign exchange rates. We use certain derivative financial instruments to help manage these exposures. We execute these instruments with financial institutions we judge to be credit-worthy. We do not hold or issue derivative financial instruments for trading or speculative purposes.

We recognize all derivative financial instruments as either assets or liabilities at fair value in the consolidated balance sheet. We have used foreign currency forward contracts as cash flow hedges of forecasted intercompany settlements denominated in foreign currencies of major industrial countries. We have no outstanding foreign currency forward contracts. We have an interest rate swap that is classified as a cash flow hedge of our variable rate debt.

Cash flow hedges Our cash flow hedge is an interest rate swap under which we agree to pay fixed rates of interest. We have no derivatives that are not accounted for as a hedging instrument. The fair value amounts in the consolidated balance sheet at June 30, 2009 were (in thousands):

	Asset Derivatives		Liability Derivatives	
	Balance Sheet Location	Fair Value	Balance Sheet Location	Fair Value
Interest rate swap	Other Assets	\$	Deferred income taxes and other long-term liabilities	\$ 1,141
Total		\$		\$ 1,141

Table of Contents

The derivative gains and losses in the consolidated statement of operations for the three months ended June 30, 2009, related to our interest rate swap contract was as follows (in thousands):

	Pretax Gain Recognized in Other Comprehensive	Pretax Loss on Effective Portion of Derivative	Ineffective Portion of Gain on Derivative and Amount Excluded from Effectiveness Testing	
Derivatives in Cash Flow	Income on	Reclassified from Accumulated Other Comprehensive	Loss	Recognized in Income
Hedging Relationships	Derivative Amount	Location	Amount	Location
Interest Rate Swap	\$ 488		\$	\$

The derivative gains and losses in the consolidated statement of operations for the six months ended June 30, 2009, related to our interest rate swap contract was as follows (in thousands):

	Pretax Gain Recognized in Other Comprehensive	Pretax Loss on Effective Portion of Derivative	Ineffective Portion of Gain on Derivative and Amount Excluded from Effectiveness Testing	
Derivatives in Cash Flow	Income on	Reclassified from Accumulated Other Comprehensive	Loss	Recognized in Income
Hedging Relationships	Derivative Amount	Location	Amount	Location
Interest Rate Swap	\$ 537		\$	\$

The notional amount of the outstanding interest rate swap was \$18,667,000. We made no adjustments to the fair value of this derivative as a result of evaluating counterparty risk.

8. FAIR VALUE MEASUREMENTS

Effective January 1, 2009, we adopted SFAS No. 157, *Fair Value Measurements* (SFAS No. 157) for our nonfinancial assets and nonfinancial liabilities measured on a non-recurring basis. We adopted SFAS No. 157 for financial assets and liabilities in 2008. The adoption of SFAS No. 157 did not have a material impact on our fair value measurements.

The following tables present our assets and liabilities that are measured at fair value on a recurring basis as of June 30, 2009 and December 31, 2008, and are categorized using the fair value hierarchy. The fair value hierarchy has three levels based on the reliability of the inputs used to determine fair value. Level 1 refers to fair values determined based on quoted prices in active markets for identical assets. Level 2 refers to fair values estimated using significant other observable inputs, and Level 3 includes fair values estimated using significant non-observable inputs.

	Fair Value Measurements at June 30, 2009			
	Total	Level 1	Level 2	Level 3
Assets				
Money market funds	\$ 22,624	\$ 22,624	\$	\$
Treasury Bills	17,103	17,103		

Auction Rate Securities	1,309			1,309
Total assets	\$ 41,036	\$ 39,727	\$	\$ 1,309
Liabilities				
Interest Rate Swap	\$ 1,141	\$	\$ 1,141	\$
Total liabilities	\$ 1,141	\$	\$ 1,141	\$

Table of Contents

	Fair Value Measurements at December 31, 2008			
	Total	Level 1	Level 2	Level 3
Assets				
Money market funds	\$ 22,560	\$ 22,560	\$	\$
Treasury Bills	9,090	9,090		
Auction Rate Securities	1,309			1,309
Total assets	\$ 32,959	\$ 31,650	\$	\$ 1,309
Liabilities				
Interest Rate Swap	\$ 1,678	\$	\$ 1,678	\$
Total liabilities	\$ 1,678	\$	\$ 1,678	\$

The fair value of the auction rate securities was estimated utilizing a discounted cash flow analysis. The discounted cash flow analysis considered, among other items, the creditworthiness of the counterparty, the timing of expected future cash flows, and the expectation of the next time the security is expected to have a successful auction. The auction rate securities were also compared to other observable market data with similar characteristics to the securities held by the Company.

9. INTANGIBLE ASSETS

(In thousands)	June 30, 2009	December 31, 2008
Amortizable intangible assets		
Patents	\$ 3,650	\$ 3,650
Customer relationships	1,908	1,655
Other identifiable intangibles	157	544
	5,715	5,849
Accumulated amortization	(1,327)	(737)
	\$ 4,388	\$ 5,112

Amortization expense for the six months ended June 30, 2009 was \$0.6 million.

The estimated future amortization expense for intangibles as of June 30, 2009 is as follows (in thousands):

2009	2010	2011	2012	2013	Thereafter
\$725	\$1,198	\$1,198	\$919	\$308	\$40

10. PRODUCT WARRANTIES

The Company typically provides one to three-year parts and service warranties on lasers and amplifiers. Most of the sales offices provide support to customers in their respective geographic areas. Warranty reserves have been generally sufficient to cover product warranty repair and replacement costs. The following table summarizes product warranty activity recorded during the six months ended June 30, 2009 and 2008 (in thousands):

	2009	2008
Beginning balance January 1	\$ 3,223	\$ 1,957
Additions for current year deliveries	1,206	1,827
Reductions for payments made	(874)	(1,050)
Impact of foreign currency fluctuation	3	65
Ending balance June 30	\$ 3,558	\$ 2,799

Table of Contents

11. COMMITMENTS AND CONTINGENCIES

In November 2006, the Company was sued for patent infringement relating to certain products, including but not limited to fiber lasers and fiber amplifiers. The plaintiff has made a complaint for damages of over \$10 million, treble damages for alleged willful infringement and injunctive relief. The case has been stayed until the termination of a pending patent re-examination.

In February 2008, the Company was sued for patent infringement relating to two product lines used in medical laser applications. The plaintiff has filed a complaint for unspecified damages, treble damages for alleged willful infringement and injunctive relief. The patent asserted in the lawsuit expired in April 2007. The case has been stayed until October 2009 in connection with a patent reexamination.

The Company believes it has meritorious defenses and intends to vigorously contest the claims. No loss is deemed probable at June 30, 2009 and no amounts have been accrued in respect of these contingencies.

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

You should read the following discussion in conjunction with our consolidated financial statements and related notes included elsewhere in this Quarterly Report on Form 10-Q. This discussion contains forward looking statements that are based on management's current expectations, estimates and projections about our business and operations. Our actual results may differ materially from those currently anticipated and expressed in such forward-looking statements. See Cautionary Statement Regarding Forward-Looking Statements.

Overview

We develop and manufacture a broad line of high-performance fiber lasers, fiber amplifiers and diode lasers for diverse applications in numerous markets. Our diverse lines of low, mid and high-power lasers and amplifiers are used in materials processing, advanced, communications and medical applications. We sell our products globally to original equipment manufacturers, or OEMs, system integrators and end users. We market our products internationally primarily through our direct sales force and also through agreements with independent sales representatives and distributors.

We are vertically integrated such that we design and manufacture all key components used in our finished products, from semiconductor diodes to optical fiber preforms, finished fiber lasers and amplifiers. Since our formation in 1990, we have been focused on developing and manufacturing high-power fiber lasers and amplifiers.

Factors and Trends That Affect Our Operations and Financial Results

In reading our financial statements, you should be aware of the following factors and trends that our management believes are important in understanding our financial performance.

Net sales. Our net sales have historically fluctuated from quarter to quarter. The increase or decrease in sales from a prior quarter can be affected by the timing of orders received from customers, the shipment, installation and acceptance of products at our customers' facilities, the mix of OEM orders and one-time orders for products with large purchase prices, and seasonal factors such as the purchasing patterns and levels of activity throughout the year in the regions where we operate. Historically, our net sales have been higher in the second half of the year than in the first half of the year. Furthermore, net sales can be affected by the time taken to qualify our products for use in new applications in the end markets that we serve. The adoption of our products by a new customer or qualification in a new application can lead to an increase in net sales for a period, which may then slow until we further penetrate new markets or obtain new customers. Our net sales can also be affected from quarter to quarter by the general level of worldwide economic activity, including economic expansion or contraction, and expenditures on capital equipment. In general, increases in worldwide economic activity have a positive effect on our sales and decreases in economic activity have a negative effect on our sales.

Gross margin. Our total gross margin in any period can be affected by total net sales in any period, product mix, that is, the percentage of our revenue in that period that is attributable to higher or lower-power products, production volumes, changes to the sales prices of our products in response to the competitive environment and by other factors, some of which are not under our control. Our product mix affects our margins because the selling price per watt is higher for low-power and mid-power devices than for high-power devices. The overall cost of high-power lasers may be partially offset by improved absorption of fixed overhead costs associated with sales of larger volumes of

higher-power products.

Table of Contents

Due to the fact that we have high fixed costs, our costs are generally difficult or slow to adjust in response to changes in demand. In addition, our fixed costs increase as we expand our capacity. Gross margins generally decline if production volumes are lower as a result of a decrease in sales or inventory because the absorption of fixed manufacturing costs will be reduced. Gross margins generally improve when the opposite occurs. In addition, absorption of fixed costs can benefit gross margins due to an increase in production that is not sold and placed into inventory. If both sales and inventory decrease in the same period, the decline in gross margin may be magnified if we cannot reduce fixed costs or chose not to reduce fixed costs to match the decrease in the level of production. We also regularly review our inventory for items that are slow-moving, have been rendered obsolete or determined to be excess. If we experience a decline in sales that reduces absorption of our fixed costs, or if we have production issues or inventory write-downs, our gross margins will be negatively affected.

Sales and marketing expense. We expect to continue to expand our worldwide direct sales organization, build and expand applications centers, hire additional personnel involved in marketing in our existing and new geographic locations, increase the number of units used for demonstration purposes and otherwise increase expenditures on sales and marketing activities in order to support the growth in our net sales. As such, we expect that our sales and marketing expenses will increase in the aggregate.

Research and development expense. We plan to continue to invest in research and development to improve our existing components and products and develop new components and products. We plan to increase the personnel involved in research and development and expect to increase other research and development expenses. As such, we expect that our research and development expenses will increase in the aggregate.

General and administrative expense. We expect our general and administrative expenses to increase moderately as we continue to invest in systems and resources to support our worldwide operations. Legal expenses vary from quarter to quarter based upon the stage of litigation, including patent re-examinations and termination of litigation stays but could increase in response to any future litigation or due to a change in status of current intellectual property matters. The timing and amount of legal expenses may vary substantially from quarter to quarter.

Major customers. We have historically depended on a few customers for a large percentage of our annual net sales. The composition of this group can change from year to year. Net sales derived from our five largest customers as a percentage of our annual net sales were 29% in 2006, 20% in 2007, 17% in 2008, and 13% for the six months ended June 30, 2009. We seek to add new customers and to expand our relationships with existing customers. We anticipate that the composition of our net sales to our significant customers will continue to change. If any of our significant customers were to substantially reduce their purchases from us, our results would be adversely affected. Our sales have been affected recently by a substantial reduction in purchases of pulsed lasers from several customers, including one what was formerly our largest customer for several years.

Results of Operations for the three months ended June 30, 2009 compared to the three months ended June 30, 2008

Overview. The worldwide economic downturn continued to negatively affected our results of operations for the three months ended June 30, 2009 as we experience continued weakness across many of our end markets, especially in materials processing. With uncertain end market demand over the longer-term, we will continue to focus on controlling costs and reducing inventories in order to maximize cash flow. At the same time, we plan to continue to build on our technology by investing in new sales and application personnel and R&D for new products.

Net sales. Net sales decreased by \$15.6 million, or 27.9%, to \$40.4 million for the three months ended June 30, 2009 from \$56.0 million for the three months ended June 30, 2008. This decrease was attributable to lower sales of fiber lasers in materials processing applications, where net sales decreased by \$16.9 million or 36.1%. This decrease was partially offset by the increases in medical applications, where net sales increased by \$0.9 million, or 99.8%, communications applications, where net sales increased by \$0.3 million or 10.2%, and sales of advanced applications, where net sales increased by \$0.1 million, or 2.2%. The decrease in materials processing applications resulted from substantially decreased sales of pulsed lasers and medium-power lasers used in marking, engraving and drilling applications. The decrease in pulsed laser sales was partially off-set by an increase in sales of high-power lasers for materials processing, particularly cutting and welding. The increase in medical is due to the increased demand from our established customer in the US and new OEM customers. The increase in communications applications sales

resulted primarily from increased sales of amplifiers, particularly in Russia. The increase in sales of advanced applications was due to higher sales of high power lasers used in government and defense research.

Cost of sales and gross margin. Cost of sales decreased by \$0.4 million, or 1.5%, to \$28.6 million for the three months ended June 30, 2009 from \$29.0 million for the three months ended June 30, 2008. Our gross margin decreased to 29.1% for the three months ended June 30, 2009 from 48.1% for the three months ended June 30, 2008. The decrease in gross margin was the result of less favorable absorption of our fixed manufacturing costs due to a decline in sales volume and reduction of inventory, increases in charges related to inventory write-downs, as well as lower sales prices due to pricing pressure caused by the industry-wide reduction in demand. These increases were offset partially by a reduction in manufacturing expenses in the period primarily related to reduced salaries and benefits expense and other manufacturing overhead. Expenses related to inventory reserves and other valuation adjustments were \$1.5 million and \$0.8 million for the three months ended June 30, 2009 and 2008, respectively.

Sales and marketing expense. Sales and marketing expense increased by \$0.2 million, or 4.8%, to \$3.9 million for the three months ended June 30, 2009 from \$3.7 million for the three months ended June 30, 2008, primarily as a result of an increase selling expenses related to depreciation of units used for demonstration purposes, premises and depreciation expenses, and sales personnel. As a percentage of sales, sales and marketing expense increased to 9.6% for the three months ended June 30, 2009 from 6.6% for the three

Table of Contents

months ended June 30, 2008. As we continue to expand our worldwide sales organization, we expect expenditures on sales and marketing to continue to increase in the aggregate although the near term increases may be more moderate.

Research and development expense. Research and development expense increased by \$0.3 million, or 6.5%, to \$4.7 million for the three months ended June 30, 2009 from \$4.4 million for the three months ended June 30, 2008. This increase was primarily due to an increase of \$0.4 million in material costs. As a percentage of sales, research and development expense increased to 11.7% for the three months ended June 30, 2009 from 7.9% for the three months ended June 30, 2008.

General and administrative expense. General and administrative expense decreased by \$0.9 million, or 14.2%, to \$4.9 million for the three months ended June 30, 2009 from \$5.8 million for the three months ended June 30, 2008, primarily due to a decrease of \$0.9 million in personnel and contractor expenses. As a percentage of sales, general and administrative expense increased to 12.2% for the three months ended June 30, 2009 from 10.3% for the three months ended June 30, 2008. We expect that legal expenses will increase in future quarters in connection with defending two patent infringement actions against the Company.

Effect of exchange rates on Sales, Gross Margin and Operating Expenses. We estimate that if exchange rates had been the same as one year ago, our second quarter 2009 sales would have been \$2.0 million higher, gross margin would have been \$1.4 million higher and operating expenses in total would have been \$0.3 million higher.

Gain (loss) on foreign exchange. Gain (loss) on foreign exchange increased by \$0.8 million to a gain of \$0.5 million for the three months ended June 30, 2009 from a loss of \$0.3 million for the three months ended June 30, 2008 and was primarily attributable to the appreciation of the Russian Ruble and Euro against the U.S. Dollar.

Interest expense. Interest expense, net was \$0.4 million for the three months ended June 30, 2009 compared to \$0.2 million for the three months ended June 30, 2008. The change in interest expense resulted from higher interest expense due to increased utilization of credit lines.

Benefit from (Provision for) income taxes. Benefit from income taxes was \$0.5 million for the three months ended June 30, 2009 compared to provision for income taxes of \$4.1 million for the three months ended June 30, 2008, representing a consistent effective tax rate of 31.0% for the three months ended June 30, 2009 and for the three months ended June 30, 2008.

Net income (loss) attributable to IPG Photonics Corporation. Net income (loss) attributable to IPG Photonics Corporation decreased by \$9.8 million to a \$1.2 million loss for the three months ended June 30, 2009 from \$8.6 million in income for the three months ended June 30, 2008.

Results of Operations for the six months ended June 30, 2009 compared to the six months ended June 30, 2008

Overview. The worldwide economic downturn negatively affected our results of operations for the six months ended June 30, 2009. With uncertain end market demand over the longer-term, we will continue to focus on controlling costs and reducing inventories in order to maximize cash flow. At the same time, we plan to continue to build on our technology by investing in new sales and application personnel and R&D for new products.

Net sales. Net sales decreased by \$23.1 million, or 21.2%, to \$85.8 million for the six months ended June 30, 2009 from \$108.9 million for the six months ended June 30, 2008. This decrease was attributable to lower sales of fiber lasers in materials processing applications, where net sales decreased by \$26.3 million or 28.9%. This decrease was partially offset by the increases sales of advanced applications, where net sales increased by \$2.0 million or 18.1% and in medical applications, where net sales increased by \$1.3 million, or 92.7%. Communications applications sales remained flat. The decrease in materials processing applications resulted from substantially decreased sales of pulsed lasers and medium-power lasers used in marking, engraving and drilling applications. The decrease in pulsed laser sales was partially offset by an increase in sales of high-power laser for materials processing, particularly cutting and welding. The increase in sales of advanced applications was due to higher sales of high power lasers used in government and defense research. The increase in medical is due to the increased demand from our established customer in the US and new OEM customers.

Cost of sales and gross margin. Cost of sales increased by \$0.7 million, or 1.1%, to \$58.2 million for the six months ended June 30, 2009 from \$57.5 million for the six months ended June 30, 2008. Our gross margin decreased to 32.2% for the six months ended June 30, 2009 from 47.2% for the six months ended June 30, 2008. The decrease in gross margin was the result of less favorable absorption of our fixed manufacturing costs due to a decline in sales

volume and reduction of inventory, increases in charges related to inventory write-downs and lower prices due to pricing pressure caused by the industry-wide reduction in demand. These increases were offset partially by a reduction in manufacturing expenses in the period primarily related to reduced salaries and benefits expense and other manufacturing supplies. Expenses related to inventory reserves and other valuation adjustments increased by \$2.6 million to \$4.2 million or 4.9% of sales for the six months ended June 30, 2009 as compared to \$1.6 million or 1.5% of sales for the six months ended June 30, 2008.

Sales and marketing expense. Sales and marketing expense increased by \$0.2 million, or 3.2%, to \$7.1 million for the six months ended June 30, 2009 from \$6.9 million for the six months ended June 30, 2008, primarily as a result of an increase in premises and depreciation expenses. As a percentage of sales, sales and marketing expense increased to 8.2% for the six months ended June 30, 2009 from 6.3% for the six months ended June 30, 2008. As we continue to expand our worldwide sales organization, we expect expenditures on sales and marketing to continue to increase in the aggregate although the near term increases may be more moderate.

Table of Contents

Research and development expense. Research and development expense increased by \$1.6 million, or 21.2%, to \$8.9 million for the six months ended June 30, 2009 from \$7.3 million for the six months ended June 30, 2008. This increase was primarily due to an increase of \$1.1 million in material costs. Research and development activity continues to focus on enhancing the performance of our internally manufactured components, refining production processes to improve manufacturing yields and the development of new products operating at different wavelengths and at higher output powers and new complimentary accessories used with our products. As a percentage of sales, research and development expense increased to 10.3% for the six months ended June 30, 2009 from 6.7% for the six months ended June 30, 2008.

General and administrative expense. General and administrative expense decreased by \$2.3 million, or 18.4%, to \$9.9 million for the six months ended June 30, 2009 from \$12.2 million for the six months ended June 30, 2008, primarily due to a decrease of \$1.3 million decrease in legal defense fees and \$1.4 million decrease in personnel and contractor expenses. We expect that legal expenses will increase in future quarters in connection with defending two patent infringement actions against the Company. As a percentage of sales, general and administrative expense increased to 11.6% for the six months ended June 30, 2009 from 11.2% for the six months ended June 30, 2008.

Effect of exchange rates on Sales, Gross Margin and Operating Expenses. We estimate that if exchange rates had been the same as one year ago, sales for the six months ended June 30, 2009 would have been \$4.1 million higher, gross margin would have been \$1.9 million higher and operating expenses in total would have been \$1.2 million higher.

(Loss) gain on foreign exchange. Loss (gain) on foreign exchange increased by \$1.3 million to a loss of \$1.0 million for the six months ended June 30, 2009 from a gain of \$0.3 million for the six months ended June 30, 2008 and was primarily attributable to the depreciation of the Russian Ruble and Euro against the U.S. Dollar.

Interest expense. Interest expense, net was \$0.8 million for the six months ended June 30, 2009 compared to \$0.3 million for the six months ended June 30, 2008. The change in interest expense resulted from higher interest expense due to increased utilization of credit lines.

Benefit from (Provision for) income taxes. Benefit from income taxes was \$63,000 for the six months ended June 30, 2009 compared to provision for income taxes of \$8.1 million for the six months ended June 30, 2008, representing an effective tax rate of 31.0% for the six months ended June 30, 2009 and 31.5% for the six months ended June 30, 2008.

Net income attributable to IPG Photonics Corporation. Net income attributable to IPG Photonics Corporation decreased by \$16.7 million to \$42,000 for the six months ended June 30, 2009 from \$16.7 million for the six months ended June 30, 2008. Net income attributable to IPG Photonics Corporation as a percentage of our net sales decreased by 15.2 percentage points to 0.1% for the six months ended June 30, 2009 from 15.3% for the six months ended June 30, 2008 due to the factors described above.

Liquidity and Capital Resources

Our principal sources of liquidity as of June 30, 2009 consisted of cash and cash equivalents of \$78.1 million, unused credit lines and overdraft facilities of \$30.6 million and working capital (excluding cash) of \$52.0 million. This compares to cash and cash equivalents of \$51.3 million, unused overdraft facilities of \$40.9 million and working capital (excluding cash) of \$80.7 million as of December 31, 2008. The increase in cash and cash equivalents of \$26.8 million from December 31, 2008 relates primarily to cash provided by operating activities during the six months ended June 30, 2009 of \$23.8 million and net proceeds from our credit lines of \$11.8 million, partially offset by capital expenditures and the acquisition of non-controlling interests totaling \$8.2 million.

We held approximately \$1.3 million in auction-rate securities (ARSs) at June 30, 2009, all of which is included in other long-term assets. Our investments in ARSs at June 30, 2009 consisted solely of taxable municipal debt securities.

As a result of continued auction failures, we have classified these as long-term available for sale securities. Additionally, we have assessed the fair value of these instruments and have identified an other-than-temporary decline in their market value related to the lack of liquidity. As a result, we carry these ARSs at approximately 86% of their face value and recorded a charge totaling \$191,000 during 2008.

Edgar Filing: IPG PHOTONICS CORP - Form 10-Q

Our long-term debt consists of an \$18.7 million secured variable-rate note which matures in July 2013. The note is secured by a mortgage on real estate and buildings in Massachusetts. We expect that the existing cash and marketable securities, our cash flows from operations and our existing lines of credit will be sufficient to meet our liquidity and capital needs for the foreseeable future. Our future long-term capital requirements will depend on many factors including our rate of net sales growth, the timing and extent of spending to support development efforts, the expansion of our sales and marketing activities, the timing and introductions of new products, the need to ensure access to adequate manufacturing capacity and the continuing market acceptance of our products. We have made no arrangements to obtain additional financing, and there is no assurance that such additional financing, if required or desired, will be available in amounts or on terms acceptable to us, if at all.

The following table details our line of credit facilities as of June 30, 2009:

Description	Total Facility	Interest Rate	Maturity	Security
U.S. Revolving Line of Credit	\$35 million	LIBOR plus 0.8% to 1.2%, depending on the Company's performance	July 2011	Unsecured
Euro Credit Facility (Germany) (1)	Euro 15.0 million (\$21.1 million)	Euribor + 1.0% or EONIA + 1.5%	June 2010	Unsecured, guaranteed by parent company
Euro Overdraft Facilities	Euro 3.2 million (\$4.5 million)	3.40%-6.95%	Between September 2009 and March 2010	Common pool of assets of German and Italian subsidiaries

(1) \$4.0 million of this credit facility is available to our Russian subsidiary and \$1.3 million is available to our Italian subsidiary

Table of Contents

The Company is required to meet certain financial covenants associated with its U.S. revolving line of credit and long term debt facilities. These covenants, tested quarterly, include a debt service coverage ratio and a funded debt to earnings before interest, taxes, depreciation and amortization (EBITDA) ratio. The debt service coverage covenant requires that we maintain a trailing twelve month ratio of cash flow to debt service that is greater than 1.5:1. Debt service is defined as required principal and interest payments during the period. Cash flow is defined as EBITDA less unfunded capital expenditures. For trailing twelve month periods until June 2010, up to \$15.0 million of our capital expenditures are treated as being funded from the proceeds of our initial public offering. The funded debt to EBITDA covenant requires that the sum of all indebtedness for borrowed money on a consolidated basis be less than two times our trailing twelve months EBITDA. We were in compliance with all such financial covenants as of June 30, 2009.

The financial covenants in our loan documents may cause us to not take or to delay investments and actions that we might otherwise undertake because of limits on capital expenditures and amounts that we can borrow or lease. In the event that we do not comply with any one of these covenants, we would be in default under the loan agreement or loan agreements, which may result in acceleration of the debt, cross-defaults on other debt or a reduction in available liquidity, any of which could harm our results of operations and financial condition.

Operating activities. Net cash provided by operating activities in the six months ended June 30, 2009 increased by \$12.2 million to \$23.8 million from \$11.6 million in the six months ended June 30, 2008. The increase in cash provided by operating activities in the first six months of 2009 compared to the first six months of 2008 primarily resulted from:

A decrease in accounts receivable of \$8.2 million in 2009 compared to an increase of \$2.8 million in 2008;

A decrease in inventory of \$1.7 million in 2009 compared to an increase of inventory of \$15.8 million in 2008; partially offset by

A decrease in cash provided by net income after adding back non-cash charges of \$14.5 million in 2009 as compared to 2008.

Given our vertical integration, rigorous and time-consuming testing procedures for both internally manufactured and externally purchased components and the lead time required to manufacture components used in our finished product, the rate at which we turn inventory has historically been low when compared to our cost of sales. We do not expect this to change significantly in the future and believe that we will have to maintain a relatively high level of inventory compared to our cost of sales. As a result, we continue to expect to have a significant amount of working capital invested in inventory and for changes in our level of inventory to lead to an increase in cash generated from our operations when it is sold or a decrease in cash generated from our operations at times when the amount of inventory is increasing. A reduction in our level of net sales or the rate of growth of our net sales from their current levels would mean that the rate at which we are able to convert our inventory into accounts receivable would decrease.

Investing activities. Net cash used in investing activities was \$7.8 million and \$14.7 million in the six months ended June 30, 2009 and 2008, respectively. The cash used in investing activities in the first six months of 2009 was related to \$7.7 million of capital expenditures on property, plant and equipment. The cash used in investing activities in the first six months of 2008 was primarily related to capital expenditures on property, plant and equipment of \$20.3 million. In 2009 and 2008, capital expenditures in the United States, Germany, and Russia related to facilities and equipment for diode wafer growth, burn-in test stations and packaging as well as new fiber assembly and component production facilities. We expect capital expenditures, excluding intangible assets, to be lower than \$15 million for the year ended December 31, 2009. The timing and extent of any capital expenditures in and between periods can have a significant effect on our cash flow. Many of the capital expenditure projects that we undertake have long lead times and are difficult to cancel or defer, with the result that it would be difficult to defer such committed capital expenditures to a later period.

Financing activities. Net cash provided by financing activities was \$11.1 million in the six months ended June 30, 2009 as compared \$10.0 million in the six months ended June 30, 2008. The cash provided by financing activities in 2009 was primarily related to the net proceeds of \$11.8 million from the use of our credit lines, partially offset by cash used to purchase noncontrolling interests of \$0.5 million. The cash provided by financing activities in 2008 was

primarily related to the net proceeds of \$8.1 million

Table of Contents

from the use of our credit lines. The increase in net drawings on credit lines in 2009 was primarily related to a plan to increase cash liquidity in response to economic uncertainties present during the six months ended June 30, 2009.

Cautionary Statement Regarding Forward-Looking Statements

This Quarterly Report on Form 10-Q contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and we intend that such forward-looking statements be subject to the safe harbors created thereby. For this purpose, any statements contained in this Quarterly Report on Form 10-Q except for historical information are forward-looking statements. Without limiting the generality of the foregoing, words such as may, will, expect, believe, anticipate, intend, estimate, or continue or the negative or other variations thereof or comparable terminology are intended to identify forward-looking statements. In addition, any statements that refer to projections of our future financial performance, trends in our businesses, or other characterizations of future events or circumstances are forward-looking statements.

The forward-looking statements included herein are based on current expectations of our management based on available information and involve a number of risks and uncertainties, all of which are difficult or impossible to accurately predict and many of which are beyond our control. As such, our actual results may differ significantly from those expressed in any forward-looking statements. Factors that may cause or contribute to such differences include, but are not limited to, those discussed in more detail in Item 1, *Business* and Item 1A, *Risk Factors* of Part I of our Annual Report on Form 10-K for the period ended December 31, 2008. Readers should carefully review these risks, as well as the additional risks described in other documents we file from time to time with the Securities and Exchange Commission. In light of the significant risks and uncertainties inherent in the forward-looking information included herein, the inclusion of such information should not be regarded as a representation by us or any other person that such results will be achieved, and readers are cautioned not to rely on such forward-looking information. We undertake no obligation to revise the forward-looking statements contained herein to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

Recent Accounting Pronouncements

In December 2007, the FASB issued SFAS No. 141 (revised 2007), *Business Combinations* (SFAS No. 141 (revised 2007)), and SFAS No. 160, *Noncontrolling Interests in Consolidated Financial Statements—an amendment of ARB No. 51* (SFAS No. 160).

SFAS No. 141 (revised 2007) requires an acquirer to measure the identifiable assets acquired, the liabilities assumed and any noncontrolling interest in the acquiree at their fair values on the acquisition date, with goodwill being the excess value over the net identifiable assets acquired. This standard also requires the fair value measurement of certain other assets and liabilities related to the acquisition such as contingencies and research and development. SFAS No. 141 (revised 2007) was required to be applied prospectively beginning January 1, 2009 and did not have a material effect on our financial statements.

SFAS No. 160 requires that a noncontrolling interest in a subsidiary be reported as a component of stockholders equity in the consolidated financial statements. Consolidated net income should include the net income for both the parent and the noncontrolling interest with disclosure of both amounts on the consolidated statement of income. The calculation of earnings per share will continue to be based on income amounts attributable to the parent. SFAS No. 160 was effective for the Company beginning January 1, 2009. The changes in presentation prescribed by SFAS No. 160 have been incorporated in the accompanying Consolidated Balance Sheets, Consolidated Statements of Operations, Consolidated Statements of Cash Flows and Consolidated Statements of Equity.

In March 2008, the FASB issued SFAS 161, *Disclosures about Derivative Instruments and Hedging Activities* (SFAS 161). SFAS 161 applies to all derivative instruments and non-derivative instruments that are designated and qualify as hedging instruments pursuant to paragraphs 37 and 42 of SFAS 133, *Accounting for Derivative Instruments and Hedging Activities* (SFAS 133), and related hedged items accounted for under SFAS 133. SFAS 161 requires additional disclosures about (a) how and why an entity uses derivative instruments, (b) how derivative instruments and related hedged items are accounted for under SFAS 133 and its related interpretations, and (c) how derivative instruments and related hedged items affect an entity's financial position, results of operations, and cash flows. SFAS 161 is effective for the Company beginning January 1, 2009. The disclosures prescribed by SFAS 161 have been included in the accompanying Notes to Consolidated Financial Statements.

Effective June 30, 2009, we adopted Statement of Financial Accounting Standards No. 165 (SFAS No. 165), *Subsequent Events*. SFAS No. 165 defines the subsequent events or transactions period, circumstances under which such events or transactions should be recognized, and disclosures regarding subsequent events or transactions. The adoption of SFAS No. 165 required the Company to provide additional disclosures stating that we consider events or transactions that occur after the balance sheet date but before the financial statements are issued to provide additional evidence relative to certain estimates or to identify matters that require additional disclosure. Subsequent events have been evaluated through August 10, 2009, the date of issuance of these financial statements.

Effective June 30, 2009, we adopted FASB Staff Position (FSP) No. FAS 107-1 and APB 28-1, *Interim Disclosures about Fair Value of Financial Instruments*, which requires disclosures about fair value of financial instruments in interim reporting periods as well as in annual financial statements. The adoption of FSP FAS 107-1 and APB 28-1 required the Company to provide additional disclosures, which are included in Note 8 in the accompanying Notes to Consolidated Financial Statements.

Table of Contents**ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK**

We are exposed to market risk in the ordinary course of business, which consists primarily of interest rate risk associated with our cash and cash equivalents and our debt and foreign exchange rate risk.

Interest rate risk. Our investments have limited exposure to market risk. To minimize this risk, we maintain a portfolio of cash, cash equivalents and short-term investments, consisting primarily of bank deposits, money market funds and short-term government funds. The interest rates are variable and fluctuate with current market conditions. Because of the short-term nature of these instruments, a sudden change in market interest rates would not be expected to have a material impact on our financial condition or results of operations.

Our exposure to market risk also relates to the increase or decrease in the amount of interest expense we must pay on our bank debt and borrowings on our bank credit facilities. The interest rates for our U.S. revolving line of credit and our Euro credit facility are variable. The rates on our Euro overdraft facilities in Germany and Italy and our Japanese Yen overdraft facility are fixed for twelve-month periods. The interest rate on our other bank debt is currently fixed through interest-rate swaps. Approximately 28% of our outstanding debt had a fixed rate of interest as of June 30, 2009. We do not believe that a 10% change in market interest rates would have a material impact on our financial position or results of operations.

Exchange rates. Due to our international operations, a significant portion of our net sales, cost of sales and operating expenses are denominated in currencies other than the U.S. dollar, principally the Euro, the Japanese Yen and the Russian Ruble. As a result, our international operations give rise to transactional market risk associated with exchange rate movements of the U.S. dollar, the Euro, the Japanese Yen and the Russian Ruble. Gains and losses on foreign exchange transactions totaled a \$0.5 million gain, and a \$0.3 million loss for the three months ended June 30, 2009 and 2008, respectively. Management believes that the use of foreign currency financial instruments reduces the risks of certain foreign currency transactions, however, these instruments provide only limited protection. We will continue to analyze our exposure to currency exchange rate fluctuations and may engage in additional financial hedging techniques in the future to attempt to minimize the effect of these potential fluctuations. Exchange rate fluctuations may adversely affect our financial results in the future. No foreign currency derivative instruments were outstanding at June 30, 2009.

ITEM 4. CONTROLS AND PROCEDURES**Evaluation of Disclosure Controls and Procedures**

Under the supervision of our chief executive officer and our chief financial officer, our management has evaluated the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) promulgated under the Securities Exchange Act of 1934, as amended (the Exchange Act)), as of the end of the period covered by this Quarterly Report on Form 10-Q (the Evaluation Date). Based upon that evaluation, our chief executive officer and our chief financial officer have concluded that, as of the Evaluation Date, our disclosure controls and procedures are effective.

Changes in Internal Controls

There was no change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) promulgated under the Exchange Act) that occurred during the last fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II OTHER INFORMATION**ITEM 1. LEGAL PROCEEDINGS**

From time to time, we are party to various legal proceedings and other disputes incidental to our business. There have been no material developments in the second quarter of 2009 with respect to those proceedings previously reported in our Annual Report on Form 10-K for the year ended December 31, 2008, except as follows:

In July 2009, the United States Patent and Trademark Office (USPTO) confirmed the patentability of all of the claims in the IMRA America Inc. patent over the prior art cited in the reexamination, as well as of new claims added during the reexamination. The U.S. District Court for the Eastern District of Michigan had previously stayed the litigation until the conclusion of the re-examination.

In June 2009, we submitted an additional reexamination request to the USPTO with respect to a patent asserted by CardioFocus Inc. against us. This request also been granted by the USPTO. The USPTO issued further office actions

in July 2009 on the two patents not expressly asserted against us in the complaint, but that were referred to in the subsequent infringement allegations against us. All of the claims of one of the two patents were rejected, as were all but three claims of the other patent, the patentability of which was confirmed. The U.S. District Court for the District of Massachusetts has stayed the litigation until the earlier of October 2009 or the conclusion of the re-examination. The Court indicated that it will consider extending the stay for up to an additional year for good cause shown.

Table of Contents**ITEM 1A. RISK FACTORS**

In addition to the other information set forth in this report, you should carefully consider the factors discussed in Part I, Item 1A. Risk Factors in our Annual Report on Form 10-K for the year ended December 31, 2008, which could materially affect our business, financial condition or future results. The risks described in our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q are not the only risks facing our Company. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition and/or operating results.

We are subject to litigation alleging that we are infringing third-party intellectual property rights. Intellectual property claims could result in costly litigation and harm our business.

In recent years, there has been significant litigation involving intellectual property rights in many technology-based industries, including our own. We face risks and uncertainties in connection with such litigation, including the risk that patents issued to others may harm our ability to do business; that there could be existing patents of which we are unaware that could be pertinent to our business; and that it is not possible for us to know whether there are patent applications pending that our products might infringe upon, since patent applications often are not disclosed until a patent is issued or published. Moreover, the frequency with which new patents are granted and the diversity of jurisdictions in which they are granted make it impractical and expensive for us to monitor all patents that may be relevant to our business.

From time to time, we have been notified of allegations and claims that we may be infringing patents or intellectual property rights owned by third parties. In 2007, we settled two patent infringement lawsuits filed against us. We are presently defending two patent infringement lawsuits. In November 2006, IMRA America, Inc. filed an action against us alleging that certain products we produce, including but not limited to our continuous wave and pulsed fiber lasers and fiber amplifiers, which account for a significant portion of our revenues, infringe one U.S. patent allegedly owned by IMRA America. IMRA America alleges willful infringement and seeks damages of at least \$10 million, treble damages and injunctive relief. IMRA America also alleges inducement of infringement and contributory infringement. We filed an answer in which we denied infringement and raised additional defenses that the patent is invalid and unenforceable. In addition, we filed declaratory judgment counterclaims based on these three defenses. This lawsuit concerns products made, used, sold or offered for sale in or imported into the United States and therefore the lawsuit affects products that account for a substantial portion of our revenues. This lawsuit does not affect revenues that are derived from products that are not made, used, sold or offered for sale in or imported into the United States. In June 2008, the U.S. Patent and Trademark Office (USPTO) ordered re-examination of the patent claims asserted by IMRA America against the Company based on several prior art references that we submitted in an *ex parte* re-examination request. In July 2009, the USPTO confirmed the patentability of all of the claims in the IMRA America patent over the prior art cited in the reexamination, as well as of new claims added during the reexamination. The U.S. District Court for the Eastern District of Michigan had previously stayed the litigation until the conclusion of the re-examination.

In February 2008, CardioFocus Inc. filed an action against us and other co-defendants alleging that our erbium and thulium fiber lasers infringe one patent allegedly owned by CardioFocus and seeks unspecified damages, treble damages and attorneys' fees for alleged willful infringement. The plaintiff also alleges inducement of infringement. The patent claims generally relate to a system for transmitting laser energy via an optical fiber to a surgical site. The patent expired in April 2007. We filed an answer in which we denied infringement and raised additional defenses that the patent is invalid and unenforceable. In addition, we filed declaratory judgment counterclaims based on these three defenses. CardioFocus subsequently alleged that the Company infringes claims of two additional patents and we are investigating a response to such allegations. We and several of our co-defendants filed reexamination requests, which were granted by the USPTO. In two office actions in November 2008, the USPTO rejected all of the claims of the CardioFocus patents alleged to be infringed. In February 2009, CardioFocus responded to the USPTO office actions, and in June 2009, we submitted an additional reexamination request to the USPTO, which request has also been granted. The USPTO issued further office actions in July 2009 on the two patents not expressly asserted against the Company in the Complaint, but that were referred to in the subsequent infringement allegations against the Company. All of the claims of one of the two patents were rejected, as were all but three claims of the other patent, the

patentability of which was confirmed. The U.S. District Court for the District of Massachusetts has stayed the litigation until the earlier of October 2009 or the conclusion of the re-examination. The Court indicated that it will consider extending the stay for up to an additional year for good cause shown. Discovery has not yet commenced.

Several outcomes are possible from the ongoing re-examinations, including the cancellation or confirmation of one or more of the current claims of the patents. Furthermore, with regard to any unexpired patents in re-examination, the current claims can be amended, and new claims can be added, provided that such amendments and additions do not enlarge the overall scope of the claims. An adverse outcome in a USPTO re-examination could have an adverse impact on our defenses in our litigation with IMRA America and/or CardioFocus.

There can be no assurance that we will be able to amicably dispose of our pending litigation with IMRA America or CardioFocus, claims or other allegations made against us and claims that may be asserted in the future. The outcome of any litigation, including the pending litigation, is uncertain, as is the outcome of the re-examination of the CardioFocus patent. Even if we ultimately are successful on the merits of any such litigation or re-examination, legal and administrative proceedings related to intellectual property are typically expensive and time-consuming, generate negative publicity and divert financial and managerial resources. Some litigants may have greater financial resources than we have and may be able to sustain the costs of complex intellectual property litigation more easily than we can.

If we do not prevail in any intellectual property litigation brought against us, including the lawsuits brought by IMRA America and CardioFocus, it could affect our ability to sell our products and materially harm our business, financial condition and results of

Table of Contents

operations. These developments could adversely affect our ability to compete for customers and increase our revenues. Plaintiffs in intellectual property cases often seek, and sometimes obtain, injunctive relief. Intellectual property litigation commenced against us, including the lawsuits brought by IMRA America and CardioFocus that we are presently defending, could force us to take actions that could be harmful to our business, competitive position, results of operations and financial condition, including the following:

stop selling our products or using the technology that contains the allegedly infringing intellectual property;

pay actual monetary damages, royalties, lost profits or increased damages and the plaintiff's attorneys' fees, which individually or in the aggregate may be substantial;

attempt to obtain a license to use the relevant intellectual property, which may not be available on reasonable terms or at all; and

attempt to redesign the products that allegedly infringed upon intellectual property of others, which may be costly or impractical.

In addition, intellectual property lawsuits can be brought by third parties against OEMs and end users that incorporate our products into their systems or processes. In some cases, we indemnify OEMs against third-party infringement claims relating to our products and we often make representations affirming, among other things, that our products do not infringe on the intellectual property rights of others. As a result, we may incur liabilities in connection with lawsuits against our customers. Any such lawsuits, whether or not they have merit, could be time-consuming to defend, damage our reputation or result in substantial and unanticipated costs.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

During the three months ended June 30, 2009, we have sold and issued 75,000 unregistered shares of common stock as partial payment of the purchase price for the 20% minority interest in IPG Photonics Japan, Ltd. that we did not previously own. IPG Photonics (Japan), Ltd. is now 100% owned by us. The aggregate sale price for the Company shares were \$838,000. The sale of securities described above was deemed to be exempt from registration pursuant to Section 4(2) of the Securities Act and Regulation D promulgated thereunder as transactions by an issuer not involving a public offering. This sale was to an accredited investor, as such term is defined in Rule 501 of Regulation D. The recipient of securities in the transaction received written disclosures that the securities had not been registered under the Securities Act and that any resale must be made pursuant to a registration or an available exemption from such registration. The sale of the securities described above did not involve the use of an underwriter, and no commissions were paid in connection with the sale of the securities that we issued. The sale of such securities was made without general solicitation or advertising.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

At the annual meeting of stockholders of IPG Photonics Corporation held on June 9, 2009, the stockholders considered and voted upon proposals to (i) re-elect the nine members of our board of directors to one-year terms, and (ii) ratify the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for 2009. Of the 42,715,229 shares present or represented by proxy at the meeting, the following numbers of shares were voted for, against, withheld or abstained:

1. **Re-election of directors:**

Nominee	Votes For	Votes Withheld
Valentin P. Gapontsev, Ph.D.	42,197,503	517,726
Eugene Shcherbakov, Ph.D.	42,261,882	453,347
Igor Samartsev	42,276,179	439,050
Robert A. Blair	42,321,078	394,151

Edgar Filing: IPG PHOTONICS CORP - Form 10-Q

Michael C. Child	42,349,767	365,462
John H. Dalton	38,530,091	4,185,138
Henry E. Gauthier	42,501,907	213,322
William S. Hurley	42,339,965	375,264
William F. Krupke, Ph.D.	41,758,952	956,277

Table of Contents

2. **Ratification of the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for 2009:**

Votes For
42,541,466

Votes Against
149,730

Abstentions
24,033

ITEM 5. OTHER INFORMATION

None.

ITEM 6. EXHIBITS

(a) Exhibits

Exhibit

No.	Description
31.1	Certification of Chief Executive Officer pursuant to Rule 13a-14(a)
31.2	Certification of Chief Financial Officer pursuant to Rule 13a-14(a)
32	Certification of Chief Executive Officer and Chief Financial Officer pursuant to Section 1350

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned thereunto duly authorized.

IPG PHOTONICS CORPORATION

Date: August 10, 2009

By: /s/ Valentin P. Gapontsev
Valentin P. Gapontsev
Chairman and Chief Executive Officer
(Principal Executive Officer)

Date: August 10, 2009

By: /s/ Timothy P.V. Mammen
Timothy P.V. Mammen
Vice President and Chief Financial
Officer
(Principal Financial Officer)